Axsome Therapeutics Inc (AXSM) — Top EPS Revision Performer
As of 2026-05-05, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 390.02%. Featured in 1 EPS revision report, most recently on 2026-05-04. Sector: Healthcare.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 390.02%
- EPS growth this year
- 46.75%
- EPS next quarter (est)
- $-0.85
- Last price
- $223.06
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-05 | 390.02% | 46.75% | $-0.85 | $223.06 |
| 2026-05-04 | 676.30% | 70.68% | $-0.59 | $223.70 |
| 2026-05-03 | 968.17% | 79.95% | $-0.81 | $206.53 |
| 2026-04-30 | 840.43% | 77.23% | $-0.84 | $207.75 |
| 2026-04-29 | 840.26% | 77.23% | $-0.84 | $183.95 |
| 2026-04-28 | 755.61% | 74.63% | $-0.86 | $185.00 |
| 2026-04-27 | 763.60% | 74.93% | $-0.84 | $187.40 |
| 2026-04-26 | 763.60% | 74.93% | $-0.84 | $185.96 |
| 2026-04-24 | 763.60% | 74.93% | $-0.84 | $185.96 |
| 2026-04-23 | 824.17% | 76.56% | $-0.83 | $182.72 |
| 2026-04-22 | 824.17% | 76.56% | $-0.83 | $186.42 |
| 2026-04-21 | 813.19% | 76.18% | $-0.83 | $182.97 |
| 2026-04-20 | 815.87% | 76.32% | $-0.83 | $188.69 |
| 2026-04-19 | 815.87% | 76.32% | $-0.83 | $188.99 |
| 2026-04-16 | 815.87% | 76.32% | $-0.83 | $184.19 |
| 2026-04-15 | 815.87% | 76.32% | $-0.83 | $184.18 |
| 2026-04-14 | 815.70% | 76.32% | $-0.83 | $184.18 |
| 2026-04-13 | 815.70% | 76.32% | $-0.83 | $178.33 |
| 2026-04-12 | 866.18% | 77.62% | $-0.82 | $178.11 |
| 2026-04-10 | 866.18% | 77.62% | $-0.82 | $178.31 |
| 2026-04-09 | 855.18% | 77.33% | $-0.82 | $178.90 |
| 2026-04-08 | 876.12% | N/A | $-0.79 | $173.19 |
| 2026-04-07 | 876.12% | N/A | $-0.79 | $168.74 |
| 2026-04-06 | 876.12% | N/A | $-0.79 | $168.74 |
| 2026-04-05 | 870.94% | N/A | $-0.79 | $168.51 |
| 2026-04-03 | 876.12% | N/A | $-0.79 | $168.74 |
| 2026-04-02 | 876.12% | N/A | $-0.79 | $168.74 |
| 2026-04-01 | 876.12% | N/A | $-0.79 | $168.74 |
| 2026-04-01 | 870.94% | N/A | N/A | $171.78 |
| 2026-04-01 | 870.94% | N/A | N/A | $171.78 |
Reports Featuring AXSM
Recent News
- Axsome Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby
- Axsome: Q1 Earnings SnapshotAssociated Press
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Summits self-inflicted stumble; Esperions take-private dealBioPharma Dive
- Summits self-inflicted stumble; Esperions take-private dealBioPharma Dive
- Axsome Therapeutics Hosts AUVELITY FDA Approval Investor Event Featuring Expert Thought LeaderGlobeNewswire
- Axsome Therapeutics Hosts AUVELITY FDA Approval Investor Event Featuring Expert Thought LeaderGlobeNewswire
- Axsome Therapeutics Announces FDA Approval of AUVELITY (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's DiseaseGlobeNewswire
- Biotech Stock Knocks At $2 Billion Opportunity, Nears Buy PointInvestor's Business Daily
EPS revision data sourced from analyst consensus estimates, refreshed daily. Axsome Therapeutics Inc (AXSM) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports